Skip to main content
Clinical Trials/ACTRN12609000440224
ACTRN12609000440224
Withdrawn
Phase 3

A multi-centre, randomised clinical trial examining the effect of Clopidogrel versus Aspirin in addition to optimal medical therapy for heart failure on subsequent heart failure hospitalisation and mortality in patients with class III-IV congestive heart failure.

niversity of Sydney0 sites1,250 target enrollmentJune 11, 2009

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Sydney
Enrollment
1250
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 11, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Men or women age \>18 years
  • 2\. Symptomatic heart failure
  • 3\. Serum N\-terminal pro\-B\-type natriuretic peptide (NT\-proBNP) of \>600pg/mL
  • OR NT\-proBNP \>400pg/mLa \+ Heart Failure (HF) hospitalisation within last 12 months
  • 4\. Treatment with an angiotensin converting enzyme (ACE) inhibitor (unless not tolerated) and ongoing treatment with a diuretic
  • 5\. Provision of written informed consent

Exclusion Criteria

  • 1\. Contraindication to aspirin or clopidogrel
  • 2\. Indication for chronic anti\-coagulation
  • 3\. Heart failure due to a reversible cause or hypertrophic or infiltrative cardiomyopathy
  • 4\. Unstable heart failure or treatment regimen
  • 5\. Life\-limiting systemic illness
  • 6\. Severe chronic obstructive pulmonary disease (COPD) (as evidenced by history of mechanical ventilation, need for home oxygen, or treatment with oral corticosteroids) for more than 3 continuous days within 12 months
  • 7\. Conditions that might interfere with protocol compliance

Outcomes

Primary Outcomes

Not specified

Similar Trials